Report of Foreign Issuer (6-k)
June 15 2018 - 6:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 6-K
__________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June, 2018
Commission File Number: 001-36619
__________________________________
Affimed N.V.
__________________________________
Im Neuenheimer Feld 582,
69120 Heidelberg,
Germany
(Address of principal executive offices)
__________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
AFFIMED N.V.
On
June 15, 2018, Affimed N.V. presented updated data in respect of AFM13 in combination with Keytruda
®
(Pembrolizumab)
in patients with relapsed/refractory Hodgkin Lymphoma at EHA.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized, in Heidelberg, Germany, June 15, 2018.
|
AFFIMED N.V.
|
|
By:
|
/s/ Adi Hoess
|
|
|
Name:
|
Adi Hoess
|
|
|
Title:
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Florian Fischer
|
|
|
Name:
|
Florian Fischer
|
|
|
Title:
|
Chief Financial Officer
|
EXHIBIT INDEX
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2024 to May 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From May 2023 to May 2024